Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc

By Akshay Kedari  Date: 2019-12-31

Lilly wins Alimta Vitamin Regimen Patent Lawsuit against Apotex Inc

 

  • Ruling by the US District Court has concluded that Apotex Inc. would be infringing the Alimta vitamin regimen patent by launching its proposed products until the patent expiration of Lilly
     
  • The ruling would bar Apotex from marketing its alternative product until the patent expiration in May 2022

American pharmaceutical company, Eli Lilly and Company, announced that the U.S. District Court (Southern District of Indiana) decided in favor of the company in the Alimta Vitamin Regimen Patent Lawsuit. The court's verdict states that Apotex Inc, a competitor would be liable for infringement of Alimta vitamin regimen patent in the event the company selling generics of the drug prior to the expiration of the patent in May 2022. 

 

Apotex is a Canadian pharmaceutical corporation producing high-quality, affordable generic, as well as innovative pharmaceuticals, for patients across the globe. The ruling would prevent Apotex from marketing its generic form of the lung cancer drug Alimta. Lilly expects the competitor company to appeal the ruling. 

 

For the record, Alimta vitamin regimen is categorized as an antifolate drug, which is designed to bar cells from making DNA through the use of folic acid.

 

Lilly's senior vice president and general counsel, Michael J. Harrington was quoted saying that the company is pleased with the District Court's ruling finding the competitor’s proposition to be a case of infringement. Commenting further on the verdict Harrington stated that Lilly deserves intellectual property protection for its extensive research efforts concentrated on the discovery of the Alimta vitamin regimen. 

 

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office had also ruled in favor of the company in 2017. Similarly, the U.S. Court of Appeals for the Federal Circuit also upheld the validity of the patent in 2017. 

 

Source credit:

https://investor.lilly.com/news-releases/news-release-details/us-district-court-rules-favor-lilly-alimta-vitamin-regimen-0

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Apple’s iPhone 13 production may take a hit due to global chip shortage

Apple’s iPhone 13 production may take a hit due to global chip shortage

By Akshay Kedari

Apple Inc. is likely to cut down production of its iPhone 13 model by approximately 10 million units on account of the global chip shortage. The American multinational technology company was previously expected to manufacture 90 million units of the ...

Israel's GoTo Global acquires German e-moped sharing platform emmy

Israel's GoTo Global acquires German e-moped sharing platform emmy

By Akshay Kedari

Israel-based multimodal vehicle sharing services provider GoTo Global Mobility Ltd. has reportedly acquired Germany’s shared e-scooter company emmy. The acquisition will allow GoTo Global to enter the German market as well as accelerate its Eur...

German airline Lufthansa adds four new planes to its A350 fleet

German airline Lufthansa adds four new planes to its A350 fleet

By Akshay Kedari

Deutsche Lufthansa AG recently revealed that it has agreed to take four new Airbus A350-900 long-haul passenger aircraft on lease, utilizing newer planes that are left grounded as airlines reorganize their balance sheets in the wake of the ...

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

Samsung fined USD 47 million by Dutch watchdog for price-fixing TVs

By Akshay Kedari

South Korean electronics manufacturing giant Samsung Electronics Co. Ltd. has been charged a penalty of USD 46.9 million by the Dutch competition watchdog Authority for Consumers and Markets (ACM) for price-fixing practices in the Netherlands. The m...

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

TEA-Lab, MED-EL unveil the world's first multifunction hearing aid app

By Akshay Kedari

Communication solution provider for cloud meetings Tencent Ethereal Audio Lab (TEA-Lab) together with Austria-quartered implantable hearing solutions leader MED-EL recently announced the launched a first-of-its-kind hearing aid app that incorporates ...